210 related articles for article (PubMed ID: 24470771)
1. Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.
Peng X; Sun P; Novick D; Andrews J; Sun S
J Pain Res; 2014; 7():37-46. PubMed ID: 24470771
[TBL] [Abstract][Full Text] [Related]
2. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
3. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.
Kim SC; Landon JE; Lee YC
Arthritis Res Ther; 2015 Jan; 17(1):18. PubMed ID: 25627453
[TBL] [Abstract][Full Text] [Related]
4. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.
Zhao Y; Sun P; Bernauer M
J Pain Res; 2012; 5():443-51. PubMed ID: 23152695
[TBL] [Abstract][Full Text] [Related]
5. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
6. Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Pain Med; 2014 Aug; 15(8):1282-93. PubMed ID: 24401017
[TBL] [Abstract][Full Text] [Related]
7. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
8. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
9. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
[TBL] [Abstract][Full Text] [Related]
10. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.
Ellis JJ; Sadosky AB; Ten Eyck LL; Cappelleri JC; Brown CR; Suehs BT; Parsons B
Clinicoecon Outcomes Res; 2014; 6():389-99. PubMed ID: 25339847
[TBL] [Abstract][Full Text] [Related]
11. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.
Sun P; Zhao Y; Zhao Z; Watson P
Curr Med Res Opin; 2011 Sep; 27(9):1793-801. PubMed ID: 21810060
[TBL] [Abstract][Full Text] [Related]
12. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
[TBL] [Abstract][Full Text] [Related]
13. Predictors of pain medication selection among patients diagnosed with fibromyalgia.
Boulanger L; Wu N; Chen SY; Nagar S; Fraser K; Bernauer MJ; Zhao Z; Zhao Y
Pain Pract; 2012 Apr; 12(4):266-75. PubMed ID: 21899718
[TBL] [Abstract][Full Text] [Related]
14. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
15. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Jan; 12(1):14-22. PubMed ID: 21615857
[TBL] [Abstract][Full Text] [Related]
16. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.
Bidari A; Moazen-Zadeh E; Ghavidel-Parsa B; Rahmani S; Hosseini S; Hassankhani A
Daru; 2019 Jun; 27(1):149-158. PubMed ID: 30877484
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin.
Kim SC; Landon JE; Solomon DH
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1813-9. PubMed ID: 23861291
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study.
Chen S; Wu N; Boulanger L; Fraser K; Zhao Z; Zhao Y
J Med Econ; 2011; 14(4):411-20. PubMed ID: 21615268
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.
Gore M; Zlateva G; Tai KS; Chandran AB; Leslie D
Pain Pract; 2011; 11(2):167-79. PubMed ID: 20723096
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia.
White C; Kwong WJ; Armstrong H; Behling M; Niemira J; Lang K
Am Health Drug Benefits; 2018 Sep; 11(6):293-301. PubMed ID: 30464796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
